References
- Morelli MB, Bongiovanni C, Da Pra S, Miano C, Sacchi F, Lauriola M, et al. Cardiotoxicity of anticancer drugs: Molecular mechanisms and strategies for cardioprotection. Front Cardiovasc Med 2022;15:847012.
- Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, et al. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin 2016;66:309-25.
- Hahn VS, Zhang KW, Sun L, Narayan V, Lenihan DJ, Ky B. Heart failure with targeted cancer therapies: Mechanisms and cardioprotection. Circ Res 2021;128:1576-93.
- Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: A systematic review and meta-analysis. Eur J Cancer 2013;49:2900-9.
- Fiuza M, Magalhães A, Menezes MN,Costa P, RibeiroLA, Abreu C, et al. Clinical experience of a cardio-oncology consultation at a tertiary university hospital in Portugal: An observational study. Rev Port Cardiol 2022;41:979-84.
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021;372:n71.
- Singh J. Critical appraisal skills programme. J Pharmacol Pharmacother 2013;4:76.
- Postigo-Martin P, Peñafiel-Burkhardt R, Gallart-Aragón T, Alcaide-LucenaM,Artacho-CordónF,Galiano-CastilloN, et al. Attenuating treatment-related cardiotoxicity in women recently diagnosed with breast cancer via a tailored therapeutic exercise program: Protocol of the ATOPE Trial. Physical Ther 2021;101:pzab014.
- Lee M, Chung W, Lee J, Park C, Park W, Song B, et al. Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin. Cancer Med 2021;10:3964-73.
- Wihandono A, Azhar Y, Abdurahman M, Hidayat S. The role of lisinopril and bisoprolol to prevent anthracycline induced cardiotoxicity in locally advanced breast cancer patients. Asian Pac J Cancer Prev 2021;22:2847-53.
- Kerrigan DJ, Reddy M, Walker EM, Cook B, McCord J, Loutfi R, et al. Cardiac rehabilitation improves fitness in patients with subclinical markers of cardiotoxicity while receiving chemotherapy: A randomized controlled study. J Cardiopulm Rehabil Prev 2022;43:129-34.
- Gongora CA, Drobni ZD, Costa Silva TQ, Zafar A, Gong J, Zlotoff DA, et al. Sodium-glucose co-transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines. JACC Heart Fail 2022;10:559-67.
- TranchitaE,MurriA,GrazioliE,CerulliC,EmerenzianiGP, Ceci R, et al. The beneficial role of physical exercise on anthracyclines induced cardiotoxicity in breast cancer patients. Cancers (Basel) 2022;14:2288.
- Cruz M, Duarte-Rodrigues J, Campelo M. Cardiotoxicity in anthracycline therapy: Prevention strategies. Rev Port Cardiol 2016;35:359-71.
- Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022;43:4229-361.